Summary
Machine-generated summaryThis Slovak public tender concerns the procurement of a medicinal product with the active substance palivizumab. Palivizumab is a recombinant humanised monoclonal antibody, supplied as 0.5 ml vials containing 50 mg. It is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in high-risk children, including children born at 35 weeks of gestation or earlier and under 6 months at the start of the RSV season, children up to 2 years treated for bronchopulmonary dysplasia in the last 6 months, and children up to 2 years with haemodynamically significant congenital heart disease.
Description
Official source
Source: TED - Tenders Electronic Daily (Publications Office of the EU)
Always verify details on the official notice.
Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 month ago
More from this buyer
Full buyer profile1 open tender right now
- Immune vaccines and immunoglobulins - Medicinal product with active substance palivizumab 2 days left
Recent awards
Similar tenders
2
days left
€352,332
est. value
4
days left
€251,287
est. value
5
days left
€5,750,000
est. value
Market context
- Avg. open tender · Medical equipment & pharmaceuticals
- €10,072,553
- Buyer track record on Aperlena
- 10 notices tracked · 3 awarded
Never miss a tender like this
25 new notices in Medical equipment & pharmaceuticals in Slovakia in the last 7 days. Get an email when new ones appear. Free.
Set up my alert